China-Biotics, Inc. Approved to List on the Nasdaq Global Market
China-Biotics expects to begin trading on the Nasdaq on October 23, 2008,until which time its common stocks will continue to trade on the Over theCounter Bulletin Board. The trading symbol for China-Biotics' common stockwill remain "CHBT."
"We are extremely proud to be approved to list on the Nasdaq GlobalMarket," said Mr. Jinan Song, China-Biotics' Chairman and Chief ExecutiveOfficer. "This upgrade to a prestigious senior exchange is a significantmilestone for China-Biotics' growth as a public company. We believe Nasdaq iswell suited for high-technology and high-growth companies like ours. Withthis milestone achieved, we hope to further enlarge our investor base andincrease both our liquidity and visibility in the investment community."
About China-Biotics, Inc.
China-Biotics, Inc. ("China-Biotics," "the Company"), a leadingmanufacturer of biotechnology products and supplements, engages in theresearch, development, marketing and distribution of probiotics dietarysupplements. Through its wholly owned subsidiary, Shanghai ShiningBiotechnology Co., Ltd., the Company has operations in Shanghai. Itsproprietary product portfolio contains live microbial nutritional supplementsunder the "Shining" brand. Currently, the products are sold OTC through largedistributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang.China-Biotics plans to launch 300 Shining brand retail outlets in major citiesin China. Currently, China-Biotics is strategically expanding its productioncapacity of probiotics to meet growing demand in the bulk additive market.For more information, please visit http://www.chn-biotics.com .
Safe Harbor Statement Under the Private Securities Litigation Reform Actof 1995: Any statements set forth above that are not historical facts areforward-looking statements that involve risks and uncertainties that couldcause actual results to differ materially from those in the forward-lookingstatements. Such factors include, but are not limited to, the Company'sability to market existing and new products, ability to access to capital forexpansion, and changes from anticipated levels of sales, future national orregional economic and competitive conditions, market acceptance of its retailstore concept, changes in relationships with customers, dependence on itsflagship product profits and other factors detailed from time to time in theCompany's filings with the United States Securities and Exchange Commissionand other regulatory authorities. The Company undertakes no obligation topublicly update or revise any forward-looking statements, whether as a resultof new information, future events or otherwise.For more information, please contact: CCG Investor Relations Crocker Coulson, President Tel: +1-646-213-1915 (New York) Email: firstname.lastname@example.org Web: http://www.ccgir.com
SOURCE China-Biotics, Inc.
You May Also Like